Personalized Medicine and Epigenomics Market
1 Study Coverage
1.1 Personalized Medicine and Epigenomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Personalized Medicine and Epigenomics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Personalized Medicine and Epigenomics Market Size for the Year 2017-2028
1.2.2 Global Personalized Medicine and Epigenomics Market Size for the Year 2017-2028
1.3 Personalized Medicine and Epigenomics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Personalized Medicine and Epigenomics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Personalized Medicine and Epigenomics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Personalized Medicine and Epigenomics Market Dynamics
1.4.1 Personalized Medicine and Epigenomics Industry Trends
1.4.2 Personalized Medicine and Epigenomics Market Drivers
1.4.3 Personalized Medicine and Epigenomics Market Challenges
1.4.4 Personalized Medicine and Epigenomics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Personalized Medicine and Epigenomics by Type
2.1 Personalized Medicine and Epigenomics Market Segment by Type
2.1.1 Reagents
2.1.2 Kits
2.1.3 Instruments
2.1.4 Enzymes
2.1.5 Services
2.2 Global Personalized Medicine and Epigenomics Market Size by Type (2017, 2022 & 2028)
2.3 Global Personalized Medicine and Epigenomics Market Size by Type (2017-2028)
2.4 United States Personalized Medicine and Epigenomics Market Size by Type (2017, 2022 & 2028)
2.5 United States Personalized Medicine and Epigenomics Market Size by Type (2017-2028)
3 Personalized Medicine and Epigenomics by Application
3.1 Personalized Medicine and Epigenomics Market Segment by Application
3.1.1 Oncology
3.1.2 Non-Oncology
3.1.3 Cancer Drug Technology
3.2 Global Personalized Medicine and Epigenomics Market Size by Application (2017, 2022 & 2028)
3.3 Global Personalized Medicine and Epigenomics Market Size by Application (2017-2028)
3.4 United States Personalized Medicine and Epigenomics Market Size by Application (2017, 2022 & 2028)
3.5 United States Personalized Medicine and Epigenomics Market Size by Application (2017-2028)
4 Global Personalized Medicine and Epigenomics Competitor Landscape by Company
4.1 Global Personalized Medicine and Epigenomics Market Size by Company
4.1.1 Top Global Personalized Medicine and Epigenomics Companies Ranked by Revenue (2021)
4.1.2 Global Personalized Medicine and Epigenomics Revenue by Player (2017-2022)
4.2 Global Personalized Medicine and Epigenomics Concentration Ratio (CR)
4.2.1 Personalized Medicine and Epigenomics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Personalized Medicine and Epigenomics in 2021
4.2.3 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Personalized Medicine and Epigenomics Headquarters, Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Personalized Medicine and Epigenomics Headquarters and Area Served
4.3.2 Global Personalized Medicine and Epigenomics Companies Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Personalized Medicine and Epigenomics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Personalized Medicine and Epigenomics Market Size by Company
4.5.1 Top Personalized Medicine and Epigenomics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Personalized Medicine and Epigenomics Revenue by Players (2020, 2021 & 2022)
5 Global Personalized Medicine and Epigenomics Market Size by Region
5.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Personalized Medicine and Epigenomics Market Size by Region (2017-2028)
5.2.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2017-2022
5.2.2 Global Personalized Medicine and Epigenomics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.1.2 North America Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Personalized Medicine and Epigenomics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.3.2 Europe Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.4.2 Latin America Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Company Details
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
7.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.1.5 Abbott Laboratories Recent Development
7.2 Affymetrix
7.2.1 Affymetrix Company Details
7.2.2 Affymetrix Business Overview
7.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
7.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.2.5 Affymetrix Recent Development
7.3 Agilent Technologies
7.3.1 Agilent Technologies Company Details
7.3.2 Agilent Technologies Business Overview
7.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
7.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.3.5 Agilent Technologies Recent Development
7.4 Astellas Pharmaceuticals
7.4.1 Astellas Pharmaceuticals Company Details
7.4.2 Astellas Pharmaceuticals Business Overview
7.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
7.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.4.5 Astellas Pharmaceuticals Recent Development
7.5 BAYER AG
7.5.1 BAYER AG Company Details
7.5.2 BAYER AG Business Overview
7.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
7.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.5.5 BAYER AG Recent Development
7.6 Bio Vision
7.6.1 Bio Vision Company Details
7.6.2 Bio Vision Business Overview
7.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
7.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.6.5 Bio Vision Recent Development
7.7 Celgene Corp.
7.7.1 Celgene Corp. Company Details
7.7.2 Celgene Corp. Business Overview
7.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
7.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.7.5 Celgene Corp. Recent Development
7.8 Emd Millipore
7.8.1 Emd Millipore Company Details
7.8.2 Emd Millipore Business Overview
7.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
7.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.8.5 Emd Millipore Recent Development
7.9 Epigenomics AG
7.9.1 Epigenomics AG Company Details
7.9.2 Epigenomics AG Business Overview
7.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
7.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.9.5 Epigenomics AG Recent Development
7.10 Epigentex
7.10.1 Epigentex Company Details
7.10.2 Epigentex Business Overview
7.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
7.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.10.5 Epigentex Recent Development
7.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
7.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
7.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
7.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
7.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
7.12 Gilead Sciences
7.12.1 Gilead Sciences Company Details
7.12.2 Gilead Sciences Business Overview
7.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
7.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.12.5 Gilead Sciences Recent Development
7.13 Glaxosmithkline
7.13.1 Glaxosmithkline Company Details
7.13.2 Glaxosmithkline Business Overview
7.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
7.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.13.5 Glaxosmithkline Recent Development
7.14 Illumina Inc.
7.14.1 Illumina Inc. Company Details
7.14.2 Illumina Inc. Business Overview
7.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
7.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.14.5 Illumina Inc. Recent Development
7.15 Johnson & Johnson
7.15.1 Johnson & Johnson Company Details
7.15.2 Johnson & Johnson Business Overview
7.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
7.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.15.5 Johnson & Johnson Recent Development
7.16 Karus Therapeutics Limited
7.16.1 Karus Therapeutics Limited Company Details
7.16.2 Karus Therapeutics Limited Business Overview
7.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
7.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.16.5 Karus Therapeutics Limited Recent Development
7.17 Laboratory Corp. Of America Holdings
7.17.1 Laboratory Corp. Of America Holdings Company Details
7.17.2 Laboratory Corp. Of America Holdings Business Overview
7.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
7.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.17.5 Laboratory Corp. Of America Holdings Recent Development
7.18 LES Laboratoires Servier
7.18.1 LES Laboratoires Servier Company Details
7.18.2 LES Laboratoires Servier Business Overview
7.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
7.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.18.5 LES Laboratoires Servier Recent Development
7.19 Merck
7.19.1 Merck Company Details
7.19.2 Merck Business Overview
7.19.3 Merck Personalized Medicine and Epigenomics Introduction
7.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.19.5 Merck Recent Development
7.20 Naturewise Biotech & Medicals Corp.
7.20.1 Naturewise Biotech & Medicals Corp. Company Details
7.20.2 Naturewise Biotech & Medicals Corp. Business Overview
7.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
7.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.20.5 Naturewise Biotech & Medicals Corp. Recent Development
7.21 Novartis Pharma AG
7.21.1 Novartis Pharma AG Company Details
7.21.2 Novartis Pharma AG Business Overview
7.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
7.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.21.5 Novartis Pharma AG Recent Development
7.22 Oncolys Biopharma Inc.
7.22.1 Oncolys Biopharma Inc. Company Details
7.22.2 Oncolys Biopharma Inc. Business Overview
7.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
7.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.22.5 Oncolys Biopharma Inc. Recent Development
7.23 Orchid Chemicals & Pharmaceuticals Limited
7.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
7.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
7.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
7.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
7.24 Progen Pharmaceuticals Limited
7.24.1 Progen Pharmaceuticals Limited Company Details
7.24.2 Progen Pharmaceuticals Limited Business Overview
7.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
7.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.24.5 Progen Pharmaceuticals Limited Recent Development
7.25 Quest Diagnostics
7.25.1 Quest Diagnostics Company Details
7.25.2 Quest Diagnostics Business Overview
7.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
7.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.25.5 Quest Diagnostics Recent Development
7.26 Roche Holding AG
7.26.1 Roche Holding AG Company Details
7.26.2 Roche Holding AG Business Overview
7.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
7.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.26.5 Roche Holding AG Recent Development
7.27 Rubicon Genomics
7.27.1 Rubicon Genomics Company Details
7.27.2 Rubicon Genomics Business Overview
7.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
7.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.27.5 Rubicon Genomics Recent Development
7.28 Takeda Pharmaceutical Company Limited
7.28.1 Takeda Pharmaceutical Company Limited Company Details
7.28.2 Takeda Pharmaceutical Company Limited Business Overview
7.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
7.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.28.5 Takeda Pharmaceutical Company Limited Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Personalized Medicine and Epigenomics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Personalized Medicine and Epigenomics Market Trends
Table 3. Personalized Medicine and Epigenomics Market Drivers
Table 4. Personalized Medicine and Epigenomics Market Challenges
Table 5. Personalized Medicine and Epigenomics Market Restraints
Table 6. Global Personalized Medicine and Epigenomics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Personalized Medicine and Epigenomics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Personalized Medicine and Epigenomics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Personalized Medicine and Epigenomics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Personalized Medicine and Epigenomics Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Personalized Medicine and Epigenomics Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Personalized Medicine and Epigenomics Revenue Share by Player, 2017-2022
Table 13. Global Personalized Medicine and Epigenomics Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Personalized Medicine and Epigenomics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2021)
Table 15. Top Players of Personalized Medicine and Epigenomics in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Personalized Medicine and Epigenomics Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Personalized Medicine and Epigenomics Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Personalized Medicine and Epigenomics Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Personalized Medicine and Epigenomics Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Personalized Medicine and Epigenomics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Personalized Medicine and Epigenomics Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Personalized Medicine and Epigenomics Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Personalized Medicine and Epigenomics Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Personalized Medicine and Epigenomics Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Personalized Medicine and Epigenomics Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Personalized Medicine and Epigenomics Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Personalized Medicine and Epigenomics Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Abbott Laboratories Company Details
Table 31. Abbott Laboratories Business Overview
Table 32. Abbott Laboratories Personalized Medicine and Epigenomics Product
Table 33. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 34. Abbott Laboratories Recent Development
Table 35. Affymetrix Company Details
Table 36. Affymetrix Business Overview
Table 37. Affymetrix Personalized Medicine and Epigenomics Product
Table 38. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 39. Affymetrix Recent Development
Table 40. Agilent Technologies Company Details
Table 41. Agilent Technologies Business Overview
Table 42. Agilent Technologies Personalized Medicine and Epigenomics Product
Table 43. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 44. Agilent Technologies Recent Development
Table 45. Astellas Pharmaceuticals Company Details
Table 46. Astellas Pharmaceuticals Business Overview
Table 47. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
Table 48. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 49. Astellas Pharmaceuticals Recent Development
Table 50. BAYER AG Company Details
Table 51. BAYER AG Business Overview
Table 52. BAYER AG Personalized Medicine and Epigenomics Product
Table 53. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 54. BAYER AG Recent Development
Table 55. Bio Vision Company Details
Table 56. Bio Vision Business Overview
Table 57. Bio Vision Personalized Medicine and Epigenomics Product
Table 58. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 59. Bio Vision Recent Development
Table 60. Celgene Corp. Company Details
Table 61. Celgene Corp. Business Overview
Table 62. Celgene Corp. Personalized Medicine and Epigenomics Product
Table 63. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 64. Celgene Corp. Recent Development
Table 65. Emd Millipore Company Details
Table 66. Emd Millipore Business Overview
Table 67. Emd Millipore Personalized Medicine and Epigenomics Product
Table 68. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 69. Emd Millipore Recent Development
Table 70. Epigenomics AG Company Details
Table 71. Epigenomics AG Business Overview
Table 72. Epigenomics AG Personalized Medicine and Epigenomics Product
Table 73. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 74. Epigenomics AG Recent Development
Table 75. Epigentex Company Details
Table 76. Epigentex Business Overview
Table 77. Epigentex Personalized Medicine and Epigenomics Product
Table 78. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 79. Epigentex Recent Development
Table 80. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
Table 81. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 82. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product
Table 83. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 84. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
Table 85. Gilead Sciences Company Details
Table 86. Gilead Sciences Business Overview
Table 87. Gilead Sciences Personalized Medicine and Epigenomics Product
Table 88. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 89. Gilead Sciences Recent Development
Table 90. Glaxosmithkline Company Details
Table 91. Glaxosmithkline Business Overview
Table 92. Glaxosmithkline Personalized Medicine and Epigenomics Product
Table 93. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 94. Glaxosmithkline Recent Development
Table 95. Illumina Inc. Company Details
Table 96. Illumina Inc. Business Overview
Table 97. Illumina Inc. Personalized Medicine and Epigenomics Product
Table 98. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 99. Illumina Inc. Recent Development
Table 100. Johnson & Johnson Company Details
Table 101. Johnson & Johnson Business Overview
Table 102. Johnson & Johnson Personalized Medicine and Epigenomics Product
Table 103. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 104. Johnson & Johnson Recent Development
Table 105. Karus Therapeutics Limited Company Details
Table 106. Karus Therapeutics Limited Business Overview
Table 107. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product
Table 108. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 109. Karus Therapeutics Limited Recent Development
Table 110. Laboratory Corp. Of America Holdings Company Details
Table 111. Laboratory Corp. Of America Holdings Business Overview
Table 112. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product
Table 113. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 114. Laboratory Corp. Of America Holdings Recent Development
Table 115. LES Laboratoires Servier Company Details
Table 116. LES Laboratoires Servier Business Overview
Table 117. LES Laboratoires Servier Personalized Medicine and Epigenomics Product
Table 118. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 119. LES Laboratoires Servier Recent Development
Table 120. Merck Company Details
Table 121. Merck Business Overview
Table 122. Merck Personalized Medicine and Epigenomics Product
Table 123. Merck Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 124. Merck Recent Development
Table 125. Naturewise Biotech & Medicals Corp. Company Details
Table 126. Naturewise Biotech & Medicals Corp. Business Overview
Table 127. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product
Table 128. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 129. Naturewise Biotech & Medicals Corp. Recent Development
Table 130. Novartis Pharma AG Company Details
Table 131. Novartis Pharma AG Business Overview
Table 132. Novartis Pharma AG Personalized Medicine and Epigenomics Product
Table 133. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 134. Novartis Pharma AG Recent Development
Table 135. Oncolys Biopharma Inc. Company Details
Table 136. Oncolys Biopharma Inc. Business Overview
Table 137. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product
Table 138. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 139. Oncolys Biopharma Inc. Recent Development
Table 140. Orchid Chemicals & Pharmaceuticals Limited Company Details
Table 141. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 142. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
Table 143. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 144. Orchid Chemicals & Pharmaceuticals Limited Recent Development
Table 145. Progen Pharmaceuticals Limited Company Details
Table 146. Progen Pharmaceuticals Limited Business Overview
Table 147. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
Table 148. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 149. Progen Pharmaceuticals Limited Recent Development
Table 150. Quest Diagnostics Company Details
Table 151. Quest Diagnostics Business Overview
Table 152. Quest Diagnostics Personalized Medicine and Epigenomics Product
Table 153. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 154. Quest Diagnostics Recent Development
Table 155. Roche Holding AG Company Details
Table 156. Roche Holding AG Business Overview
Table 157. Roche Holding AG Personalized Medicine and Epigenomics Product
Table 158. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 159. Roche Holding AG Recent Development
Table 160. Rubicon Genomics Company Details
Table 161. Rubicon Genomics Business Overview
Table 162. Rubicon Genomics Personalized Medicine and Epigenomics Product
Table 163. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 164. Rubicon Genomics Recent Development
Table 165. Takeda Pharmaceutical Company Limited Company Details
Table 166. Takeda Pharmaceutical Company Limited Business Overview
Table 167. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product
Table 168. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 169. Takeda Pharmaceutical Company Limited Recent Development
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Personalized Medicine and Epigenomics Product Picture
Figure 2. Global Personalized Medicine and Epigenomics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Personalized Medicine and Epigenomics Market Size 2017-2028 (US$ Million)
Figure 4. United States Personalized Medicine and Epigenomics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Personalized Medicine and Epigenomics Market Size 2017-2028 (US$ Million)
Figure 6. United States Personalized Medicine and Epigenomics Market Share in Global 2017-2028
Figure 7. Personalized Medicine and Epigenomics Report Years Considered
Figure 8. Product Picture of Reagents
Figure 9. Product Picture of Kits
Figure 10. Product Picture of Instruments
Figure 11. Product Picture of Enzymes
Figure 12. Product Picture of Services
Figure 13. Global Personalized Medicine and Epigenomics Market Share by Type in 2022 & 2028
Figure 14. Global Personalized Medicine and Epigenomics Market Size by Type (2017-2028) & (US$ Million)
Figure 15. Global Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
Figure 16. United States Personalized Medicine and Epigenomics Market Share by Type in 2022 & 2028
Figure 17. United States Personalized Medicine and Epigenomics Market Size by Type (2017-2028) & (US$ Million)
Figure 18. United States Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
Figure 19. Product Picture of Oncology
Figure 20. Product Picture of Non-Oncology
Figure 21. Product Picture of Cancer Drug Technology
Figure 22. Global Personalized Medicine and Epigenomics Market Share by Application in 2022 & 2028
Figure 23. Global Personalized Medicine and Epigenomics Market Size by Application (2017-2028) & (US$ Million)
Figure 24. Global Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
Figure 25. United States Personalized Medicine and Epigenomics Market Share by Application in 2022 & 2028
Figure 26. United States Personalized Medicine and Epigenomics Market Size by Application (2017-2028) & (US$ Million)
Figure 27. United States Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
Figure 28. North America Personalized Medicine and Epigenomics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 29. U.S. Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 30. Canada Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Europe Personalized Medicine and Epigenomics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 32. Germany Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. France Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. U.K. Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Italy Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Russia Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Personalized Medicine and Epigenomics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 38. China Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Japan Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. South Korea Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. India Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Australia Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Taiwan Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Indonesia Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Thailand Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Malaysia Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Philippines Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Latin America Personalized Medicine and Epigenomics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 49. Mexico Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Brazil Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Argentina Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Personalized Medicine and Epigenomics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 53. Turkey Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. UAE Personalized Medicine and Epigenomics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 57. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 58. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 59. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 60. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 61. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 62. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 63. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 64. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 65. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 66. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 67. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 68. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 69. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 70. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 71. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 72. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 73. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 74. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 75. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 76. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 77. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 78. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 79. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 80. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 81. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 82. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 83. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Industry Market Size
